Administrative

UCSF自身免疫卓越中心（ACE）的行政单位包括： 在NIH中心赠款管理方面具有丰富经验的人员。校长 研究者，大卫沃夫西博士，曾担任PI的UCSF ACE赠款在本周期;之前， 他在加州大学旧金山分校多功能关节炎和肌肉骨骼疾病中心担任了10年的PI （MAMDC）通过NIAMS授予。因此，他在领导多项目NIH方面非常有经验 程序. Wofsy博士将负责UCSF中心的监督，并将担任临床 从加州大学旧金山分校到ACE计划的研究代表。Jeffrey Bluestone博士，行政部门的联合Pi 单位，也有丰富的经验，在复杂的计划赠款的管理，证明了他的 NIAID免疫耐受网络主任。布鲁斯通博士将作为基础研究 从UCSF到ACE计划的代表。沃夫斯博士和布鲁斯通博士将加入他们的领导层 Maria Dall'Era博士，医学部临床试验中心主任，该中心将容纳 大多数临床试验沃夫西·布鲁斯通博士和达尔·埃拉博士将协助他们履行职责 由韦内西亚雅各布斯。雅各布斯女士一直担任赠款经理为我们的ACE计划在整个目前 因此，她非常熟悉管理这个复杂程序的复杂性。 Drs.沃夫西和布鲁斯通特别有资格领导一个ACE项目，因为他们两人都 真正弥合自身免疫性疾病基础研究和临床研究之间的差距。沃夫西博士致力于 在他职业生涯的前二十年，他致力于在小鼠模型中研究新的治疗策略， 红斑狼疮（SLE），然后将他的研究重点转移到临床治疗的设计和实施。 SLE患者的治疗方法。他已经证明了他的能力，翻译有前途的工作在小鼠模型， 通过领导几项主要试验，最值得注意的是一项联合试验， ACE/ITN CTLA 4lg试验，该试验源于他先前的实验室研究。同样，布鲁斯通博士 他成功地将他在糖尿病小鼠模型中的工作带入了糖尿病新疗法的大型多中心试验， 糖尿病患者沃夫西博士和布鲁斯通博士不仅非常适合行政方面的工作， 领导这个项目，但他们也有资格为其他研究人员提供科学指导， 他的节目。

The Administrative Unit for the proposed UCSF Autoimmunity Center of Excellence (ACE) consists of personnel who have extensive experience in the administration of NIH Center grants. The principal investigator, Dr. David Wofsy, has served as PI for the UCSF ACE grant during the current cycle; prior to that, he served for 10 years as PI for the UCSF Multipurpose Arthritis and Musculoskeletal Diseases Center (MAMDC) grant through NIAMS. Thus, he is very experienced in the leadership of multi-project NIH programs. Dr. Wofsy will be responsible for oversight of the UCSF Center and will serve as the clinical research representative from UCSF to the ACE program. Dr. Jeffrey Bluestone, co-Pi for the Administrative Unit, also has extensive experience in the administration of complex program grants, as evidenced by his role as Director of the NIAID Immune Tolerance Network. Dr. Bluestone will serve as the basic research representative from UCSF to the ACE program. Drs. Wofsy and Bluestone will be joined in their leadership roles by Dr. Maria Dall'Era, Director of the Department of Medicine Clinical Trials Center which will house most of our clinical trials. Drs. Wofsy Bluestone, and Dall'Era will be assisted in fulfilling their responsibilities by Venecia Jacobs. Ms. Jacobs has served as grants manager for our ACE program throughout the current cycle, so she is very familiar with the intricacies of administering this complex program. Drs. Wofsy and Bluestone are particularly well-qualified to lead an ACE program, in that both of them genuinely bridge the gap between basic and clinical research in autoimmune diseases. Dr. Wofsy devoted he first two decades of his career to studies of new therapeutic strategies in murine models for systemic upus erythematosus (SLE), before shifting the emphasis of his research to the design and conduct of clinical rials for people with SLE. He has demonstrated his ability to translate promising work in murine models for SLE into multicenter collaborative clinical trials in humans by leading several major trials, most notably a joint ACE/ITN trial of CTLA4lg that arose out of his prior laboratory-based research. Similarly, Dr. Bluestone has successfully carried his work in murine models for diabetes into large multicenter trials of new therapies for people with diabetes. Drs. Wofsy and Bluestone are thus not only well-suited to the administrative aspects of leading this program, but they are also well-qualified to provide scientific guidance to other investigators in his program.